Axsome Therapeutics, Inc. – NASDAQ:AXSM
Founder-led company
Axsome Therapeutics stock price today
$112
+25.29
+29.18%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market open
Closed in about 2 hours
Axsome Therapeutics stock price monthly change
+4.67%
month
Axsome Therapeutics stock price quarterly change
+4.67%
quarter
Axsome Therapeutics stock price yearly change
+3.70%
year
Axsome Therapeutics key metrics
Market Cap | 4.24B |
Enterprise value | 2.54B |
P/E | -12.96 |
EV/Sales | 50.87 |
EV/EBITDA | -14.38 |
Price/Sales | 52.99 |
Price/Book | 24.20 |
PEG ratio | 0.39 |
EPS | -6.38 |
Revenue | 251.02M |
EBITDA | -304.10M |
Income | -296.37M |
Revenue Q/Q | -20.69% |
Revenue Y/Y | 73.58% |
Profit margin | -373.99% |
Oper. margin | -352.74% |
Gross margin | 89.61% |
EBIT margin | -352.74% |
EBITDA margin | -121.14% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeAxsome Therapeutics stock price history
Axsome Therapeutics stock forecast
Axsome Therapeutics financial statements
Average Price Target
$133.4
Potential upside: 19.10%
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 46.7M | -67.17M | -143.83% |
|---|---|---|---|
| Sep 2023 | 57.79M | -62.19M | -107.62% |
| Dec 2023 | 71.53M | -98.65M | -137.92% |
| Mar 2024 | 74.99M | -68.35M | -91.14% |
| Jun 2023 | 611638000 | 332.83M | 54.42% |
|---|---|---|---|
| Sep 2023 | 600857000 | 331.34M | 55.15% |
| Dec 2023 | 588236000 | 397.25M | 67.53% |
| Mar 2024 | 545728000 | 401.69M | 73.61% |
| Jun 2023 | -55.34M | -133K | 246.08M |
|---|---|---|---|
| Sep 2023 | -53.54M | -371K | 33.37M |
| Dec 2023 | -30.36M | -7K | -2K |
| Mar 2024 | -53.46M | -98K | -1.18M |
Axsome Therapeutics alternative data
| Aug 2023 | 393 |
|---|---|
| Sep 2023 | 422 |
| Oct 2023 | 422 |
| Nov 2023 | 422 |
| Dec 2023 | 502 |
| Jan 2024 | 502 |
| Feb 2024 | 502 |
| Apr 2024 | 545 |
| May 2024 | 545 |
| Jun 2024 | 569 |
| Jul 2024 | 569 |
Axsome Therapeutics other data
29.87%
-42.18%
of AXSM is owned by hedge funds
122
-93
12.14M
-17.90M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Apr 2024 | 0 | 24662 |
| May 2024 | 0 | 18407 |
| Aug 2024 | 0 | 47739 |
| Sep 2024 | 0 | 11016 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Option | COLEMAN MARK director | Common Stock | 33,410 | $5.94 | $198,455 | ||
Option | COLEMAN MARK director | Stock Option (Right to Buy) | 33,410 | $5.94 | $198,455 | ||
Option | SAAD MARK E director | Common Stock | 11,016 | $3.67 | $40,429 | ||
Sale | SAAD MARK E director | Common Stock | 11,016 | $91.31 | $1,005,871 | ||
Option | SAAD MARK E director | Stock Option (Right to Buy) | 11,016 | $3.67 | $40,429 | ||
Option | JACOBSON MARK L. officer: Chief Op.. | Common Stock | 47,739 | $4.04 | $192,866 | ||
Option | JACOBSON MARK L. officer: Chief Op.. | Common Stock | 47,739 | $4.04 | $192,866 | ||
Sale | JACOBSON MARK L. officer: Chief Op.. | Common Stock | 47,739 | $84.26 | $4,022,488 | ||
Sale | JACOBSON MARK L. officer: Chief Op.. | Common Stock | 47,739 | $84.26 | $4,022,488 | ||
Option | JACOBSON MARK L. officer: Chief Op.. | Stock Option (Right to Buy) | 47,739 | $4.04 | $192,866 |
| Patent |
|---|
Application Filling date: 23 May 2022 Issue date: 8 Sep 2022 |
Grant Filling date: 13 Dec 2021 Issue date: 6 Sep 2022 |
Grant Filling date: 7 Dec 2021 Issue date: 6 Sep 2022 |
Grant Filling date: 22 Jun 2020 Issue date: 6 Sep 2022 |
Grant Filling date: 21 Jul 2021 Issue date: 30 Aug 2022 |
Application Filling date: 25 Apr 2022 Issue date: 18 Aug 2022 |
Application Filling date: 27 Apr 2022 Issue date: 11 Aug 2022 |
Application Filling date: 26 Apr 2022 Issue date: 11 Aug 2022 |
Application Filling date: 29 Nov 2021 Issue date: 11 Aug 2022 |
Application Filling date: 19 Apr 2022 Issue date: 4 Aug 2022 |
| Quarter | Transcript |
|---|---|
| Q1 2024 6 May 2024 | Q1 2024 Earnings Call Transcript |
| Q4 2023 20 Feb 2024 | Q4 2023 Earnings Call Transcript |
| Q3 2023 6 Nov 2023 | Q3 2023 Earnings Call Transcript |
| Q2 2023 7 Aug 2023 | Q2 2023 Earnings Call Transcript |
| Insider | Compensation |
|---|---|
| Dr. Herriot Tabuteau M.D. (1968) Founder, Chairman, Chief Executive Officer & Pres | $1,020,000 |
Mr. Nick Pizzie CPA, M.B.A. (1975) Chief Financial Officer | $570,000 |
| Mr. Mark L. Jacobson (1983) Chief Operating Officer & Sec. | $570,000 |
Axsome Therapeutics Remains A Buy Despite AXS-05's Mixed Results
3 Of My Favorite Names On Wells Fargo's Biotech Buyout List
Why Axsome Therapeutics Is A Promising Stock Pick In CNS Treatments
Neurocrine: Success Continues To Roll In With Positive MDD Treatment Data
Intra-Cellular: More Upside Possible Even After Positive MDD Treatment Data
Lundbeck On A Better Path, But With Some Risks
Axsome: Show Me Another Company With Such A Stack Of Catalysts
Axsome Update: Buy At Dips And Hold Forever
Axsome Therapeutics: 'Buy' The Auvelity Launch (Rating Upgrade)
-
What's the price of Axsome Therapeutics stock today?
One share of Axsome Therapeutics stock can currently be purchased for approximately $112.
-
When is Axsome Therapeutics's next earnings date?
Unfortunately, Axsome Therapeutics's (AXSM) next earnings date is currently unknown.
-
Does Axsome Therapeutics pay dividends?
No, Axsome Therapeutics does not pay dividends.
-
How much money does Axsome Therapeutics make?
Axsome Therapeutics has a market capitalization of 4.24B and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 440.8% to 270.6M US dollars.
-
What is Axsome Therapeutics's stock symbol?
Axsome Therapeutics, Inc. is traded on the NASDAQ under the ticker symbol "AXSM".
-
What is Axsome Therapeutics's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Axsome Therapeutics?
Shares of Axsome Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Axsome Therapeutics's key executives?
Axsome Therapeutics's management team includes the following people:
- Dr. Herriot Tabuteau M.D. Founder, Chairman, Chief Executive Officer & Pres(age: 57, pay: $1,020,000)
- Mr. Nick Pizzie CPA, M.B.A. Chief Financial Officer(age: 50, pay: $570,000)
- Mr. Mark L. Jacobson Chief Operating Officer & Sec.(age: 42, pay: $570,000)
-
Is Axsome Therapeutics founder-led company?
Yes, Axsome Therapeutics is a company led by its founder Dr. Herriot Tabuteau M.D..
-
How many employees does Axsome Therapeutics have?
As Jul 2024, Axsome Therapeutics employs 569 workers, which is 4% more then previous quarter.
-
When Axsome Therapeutics went public?
Axsome Therapeutics, Inc. is publicly traded company for more then 9 years since IPO on 19 Nov 2015.
-
What is Axsome Therapeutics's official website?
The official website for Axsome Therapeutics is axsome.com.
-
Where are Axsome Therapeutics's headquarters?
Axsome Therapeutics is headquartered at 22 Cortlandt Street, New York, NY.
-
How can i contact Axsome Therapeutics?
Axsome Therapeutics's mailing address is 22 Cortlandt Street, New York, NY and company can be reached via phone at +212 3323241.
-
What is Axsome Therapeutics stock forecast & price target?
Based on 5 Wall Street analysts` predicted price targets for Axsome Therapeutics in the last 12 months, the avarage price target is $133.4. The average price target represents a 19.10% change from the last price of $112.
Axsome Therapeutics company profile:
Axsome Therapeutics, Inc.
axsome.comExchange:
NASDAQ
Full time employees:
607
Industry:
Biotechnology
Sector:
Healthcare
Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's product pipeline includes AXS-05, a therapeutic for the treatment of major depressive disorder and resistant depression disorders; and that is in the Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation. It is also developing AXS-07, a novel, oral, rapidly absorbed, multi-mechanistic, and investigational medicine that has completed two Phase III trials for the acute treatment of migraine; AXS-12, a selective and potent norepinephrine reuptake inhibitor, which is in Phase III trial to treat narcolepsy; and AXS-14, a novel, oral, and investigational medicine that is in Phase III trial for the treatment of fibromyalgia. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.
22 Cortlandt Street
New York, NY 10007
New York, NY 10007
CIK: 0001579428
ISIN: US05464T1043
CUSIP: 05464T104
